Clinical Trials Directory

Trials / Terminated

TerminatedNCT01770665

Validation of the MiCK Assay

Mayo Clinic Validation of the MiCK Assay

Status
Terminated
Phase
Study type
Observational
Enrollment
21 (actual)
Sponsor
Pierian Biosciences · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Testing Mayo Clinic cancer patients with the results being correlated with prior patient therapy, performance status, and extent of disease.

Detailed description

This study will be conducted in two phases. During the Feasibility Phase, specimens from any tumor will be sent to the central DiaTech MiCK assay laboratory to determine the ease of sample acquisition, processing, transport, and assay interpretation. Once DiaTech has completed analyses for the feasibility phase specimens and has confirmed that the sample acquisition, processing, transport, and assay interpretation are appropriate, we will proceed with the Demonstration Phase. During the Mesothelioma Demonstration Phase, 20 mesothelioma samples will be assayed and the results will be correlated with prior patient therapy, performance status, and extent of disease.

Conditions

Timeline

Start date
2012-06-01
Primary completion
2015-01-01
Completion
2016-09-01
First posted
2013-01-18
Last updated
2016-09-16

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01770665. Inclusion in this directory is not an endorsement.

Validation of the MiCK Assay (NCT01770665) · Clinical Trials Directory